Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

Video

Related Videos
Erin Crane, MD, MPH
Núria Agustí Garcia, MD
Yang Yang Hartwich, PhD
Gottfried Konecny, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Gottfried Konecny, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Related Content
Emil Lou, MD, PhD, FACP, of University of Minnesota Medical School

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024
Article
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023
Podcast
R. Wendel Naumann, MD

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024
Article
Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022
Podcast
John Friend, MD

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024
Article
Gottfried E. Konecny, MD, medical oncologist, Department of Gynecologic Medical Oncology, lead clinician, gynecologic oncology, University of California, Los Angeles, UCLA Health Jonsson Comprehensive Cancer Center

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024
Article